Market Trends of Lithotripsy Device Industry
Extracorporeal Shock Wave Lithotripsy (ESWL) Devices Segment Expected to Have a Significant Market Share
Extracorporeal shock wave lithotripsy is a technique for treating stones in the kidney and ureter that do not require surgery. Instead, high-energy shock waves are passed through the body and used to break stones into pieces as small as grains of sand. Extracorporeal shock wave lithotripsy devices (ESWL) are used for the treatment of kidney and ureter stones. This technology has been utilized by physicians worldwide and is expected to increase its penetration over the coming years due to the advantages offered, such as minimal invasiveness, reduced pain, shorter hospital stays, and quicker recovery time. Generally, this procedure is considered safe and less time-consuming as it takes only 45 minutes to perform. The growing demand for non-invasive procedures is leading to the adoption of ESWL. A study published in the Journal Disease Markers in July 2022 highlighted the high efficacy of ESWL for the management of urinary calculi. The study further highlighted the safety, and lower low incidence of adverse events, after the procedure. Further, a study published in the Urolithiasis in January 2023, underlines the minimally invasive nature of the ESWL procedure and its wide usage. The study stated that over 92% of the kidney stones patients covered in the study had their kidney stones cleared after the ESWL procedure.
Further, the key developments in the extracorporeal shock wave lithotripsy segment is also expected to boost the growth of the segment. For instance, in September 2022, Advanced MedTech Holdings, the acquired the WIKKON, Chinese company of urology and shock wave therapy devices. The acquisition would strengthen the extracorporeal shock wave lithotripsy portfolio of Advanced MedTech Holdings with the WIKKON advanced portfolio of urological solutions. Further, in June 2021, STORZ MEDICAL received the FDA 510 (k) clearance for its MODULITH SLX-F2 extracorporeal shock wave lithotripter for the new indications. With the FDA 510 (k) clearance the extracorporeal shock wave lithotripter would be able to offer non-invasive treatment of kidney stone.
Therefore, the extracorporeal shock wave lithotripsy segment is expected to witness significant growth over the forecast period due to the abovementioned factors, including its usage in the management of kidney stones and key developments in the segment.
North America Holds the Significant Share of the Lithotripsy Device Market
In North America, the lithotripsy devices market is projected to witness growth over the forecast period. Chronic kidney diseases are estimated to be more common in women than men. The number of chronic kidney diseases is found to be increasing globally. Kidney disease statistics for the US convey the burden of chronic kidney disease (CKD) and end-stage renal disease (ESRD). According to the data published by the Centers for Disease Control and Prevention, in July 2022, around 37 million people, i.e., 1 out of every 7, or 15% of the adult population, were estimated to have chronic kidney diseases. With the increasing cases of kidney disease, over 50,000 lithotripsy procedures are completed annually in the United States, which helps drive the lithotripsy devices market. A study published in the journal Medicina by the researchers of Mexico, in March 2022, highlighted the high prevalence and recurrence of Nephrolithiasis and the required surgical interventions in the population of Southeast Mexico.
Further, the developments and investment in the region are also expected to boost the growth of the lithotripsy market in North America. For instance, in July 2022, a United States based medical device company that is focused on kidney care and kidney stones management, received funding of USD 32.7 million in the Series C financing round led by Questa Capital and CR Group L.P. (CRG). Further, in November 2022, Adventist Health Hanford invested over USD 250,000 into the new laser technology for the treatment of kidney stones. Under the investment, the hospital would purchase Lumenis Pulse 120H Holmium Laser System with MOSES Technology which is capable to offer faster procedures by saving 20% of the time, less use of anesthesia, faster recovery times, and ease of treating outpatients without a hospital stay.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
